NCT04677855View on ClinicalTrials.gov

Study of PCUR-101 in Combination With ADT in Patients With mCRPC

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 30, 2021

Primary Completion Date

October 23, 2023

Study Completion Date

November 20, 2023

Conditions
Prostate Cancer
Interventions
DRUG

PCUR-101

50 mg capsules

DRUG

Dutasteride 0.5 mg

0.5 mg capsules

DRUG

Abiraterone and Prednisone

500 mg tablets Abiraterone with 5 mg Prednisone Tablets

Trial Locations (4)

2217

St. George Private Hospital, Kogarah

5042

Southern Oncology Clinical Research, Bedford Park

48109

University of Michigan, Ann Arbor

68130

Nebraska Cancer Specialist, Omaha

Sponsors
All Listed Sponsors
lead

Pellficure Pharmaceuticals, Inc

INDUSTRY

NCT04677855 - Study of PCUR-101 in Combination With ADT in Patients With mCRPC | Biotech Hunter | Biotech Hunter